$BLGO Balance Sheet | Understand Stock

$BLGO

$0.09 -$0.00 (2.78%) Close

$BLGO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets (Current Period Unaudited)

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Current assets:
Cash and cash equivalents
Accounts receivable, net of allowances
Note receivable
Inventories
Prepaid expenses and other current assets
Total current assets
In-process research and development (Note 9)
Equipment and leasehold improvements, net
Other non-current assets
Operating lease right-of-use assets, net
Clyra Medical prepaid marketing (Note 10)
Total non-current assets
Financing lease right-of-use asset, net
Note receivable, net of current
Partially Owned Subsidiary
Entities, Excluding Partially Owned Subsidiary
Total note receivable, net of current
Investment in South Korean joint venture
Total assets

Current liabilities:
Accounts payable and accrued expenses
Partially Owned Subsidiary
Entities, Excluding Partially Owned Subsidiary
Total accounts payable and accrued expenses
Debt obligations
Partially Owned Subsidiary
Clyra Medical Debt Obligations
Entities, Excluding Partially Owned Subsidiary
Debt Obligations
Total debt obligations

Debt obligation
Contract liabilities
Customer deposits
Lease liability
Partially Owned Subsidiary
Total lease liability
Operating lease liabilities
Finance lease liability
Deposits
Total current liabilities

Long-term liabilities:
Debt obligations, net of current
Partially Owned Subsidiary
Entities, Excluding Partially Owned Subsidiary
Debt Obligations
Total debt obligations, net of current
Operating lease liabilities, net of current
Common stock held for redemption (Note 9)
Finance lease liability, net of current
Total long-term liabilities
Total liabilities

STOCKHOLDERS’ (DEFICIT) EQUITY:
Preferred Series A, $0.00067 Par Value, 50,000,000 Shares Authorized, no Shares Issued and Outstanding, at June 30, 2026 and December 31, 2025
Common stock, $0.00067 Par Value, 550,000,000 Shares Authorized, 325,231,362 and 317,377,777 Shares Issued, at June 30, 2026 and December 31, 2025
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Total BioLargo Inc. and subsidiaries stockholders’ (deficit) equity
Non-controlling interest (Notes 8, 9, 10, 11)
Total stockholders’ (deficit) equity
Total liabilities and stockholders’ (deficit) equity

Comments